University of Heidelberg
Germany to Test Genomics-Based Precision Medicine for Cancer, Rare Disease in National Pilot Project
Premium
With reimbursement from public health insurance, the "model project" will run for at least five years and examine the utility of genomic sequencing for advanced cancer and rare disease patients.
Beset by COVID-19 Pandemic, Europe Searches for Right Test Mix for Diagnosis, Surveillance
Some parts of Europe turned to serology testing early to try to get a handle on the pandemic but had to quickly pull back after those tests performed abysmally.
The method uses nanopore sequencing to analyze short cell-free DNA fragments from blood, providing results in as little as six hours.
In a recent publication, the researchers assessed clinical data from 3,000 late-stage NSCLC patients after performing DNA and RNA sequencing on their tissue samples.
Heidelberg Cancer Collaboration Enables Targeted and Comprehensive Molecular Tumor Profiling
Premium
A partnership involving Heidelberg University Hospital, the National Center for Tumor Diseases, and the German Cancer Research Institute is serving patients across Germany.